Jazz Pharmaceuticals JAZZ Payments to Acquire In Process Research and Development Other Than Through Business Combination

Discontinued — last reported Q4 '25

Payments to Acquire In Process Research and Development Other Than Through Business Combination at other companies

Halozyme TherapeuticsHALO

$71.94M—

Johnson & JohnsonJNJ

$96.25M-78.4%

Cboe Global MarketsCBOE

$0-100%

Mid-America Apartment CommunitiesMAA

$75.26M+13.6%

ViatrisVTRS

-$6M+60.0%

BrukerBRKR

$7.35M—

Other financials

Income statement

See full

Revenue$1.1B+19.1%

Operating income$336.6M+702%

Net income$293.1M+417%

EPS (diluted)$4.43+391%

Balance sheet

See full

Cash & equivalents$667.5M-64.1%

Total debt$5.4B-0.1%

Total equity$4.5B+8.6%

Total assets$11.9B+2.8%

Cash flow

See full

Operating cash flow$408.2M-5.0%

CapEx$19.7M+41.7%

Free cash flow$388.5M-6.6%

Valuation

See full

Market cap$14.11B+54.4%

Enterprise value$18.85B+47.7%

P/S3.2×+0.9×

Profitability

See full

Operating margin-11.9%-28.1pp

Net margin-8.9%-20.5pp

FCF margin28.6%-8.6pp

Returns & leverage

See full

Return on equity-9.1%-21.2pp

Debt / equity1.2×-0.1×

Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's payments to acquire in process research and development other than through business combination.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Jazz Pharmaceuticals's payments to acquire in process research and development other than through business combination?: Jazz Pharmaceuticals (JAZZ) reported payments to acquire in process research and development other than through business combination of $10.63M in Q4 2025.
What does payments to acquire in process research and development other than through business combination mean?: Cash payments made to acquire research and development projects that are currently in progress but have not yet reached commercial viability. This is a key indicator of a company's commitment to external innovation and pipeline replenishment.